Background: The aim of this study was to summarize our singlecenter real-world experience with percutaneous coronary intervention (PCI) stenting of unprotected left main coronary artery (ULM-CA). PCI-stenting of the ULMCA, while controversial, is emerging as an alternative to coronary artery bypass graft (CABG) surgery in select patients and clinical situations.
Introduction
Left main coronary artery (LMCA) stenoses are found in 3-10% of patients undergoing coronary angiography [1, 2] . Medical treatment results in one year mortality of 21% [3] and three year mortality of 30-40% [4] [5] [6] [7] . Coronary artery bypass graft surgery (CABG) leads to improved long-term survival [4] [5] [6] [7] and continues to be the recommendation for the treatment of unprotected LMCA lesions [8] . ULMCA PCI has been upgraded to a Class IIb recommendation according to American College of Cardiology/American Heart Association guidelines for patients not suitable for CABG.
Methods

Study design
This is a prospective registry study looking at patients in a "real world" application undergoing PCI-stenting of LMCA lesions at Dartmouth-Hitchcock Medical Center, an academic rural regional medical center. Patients were identified at the time of the procedure with demographic, clinical, angiographic, and procedural data and followed prospectively in the Dartmouth Dynamic Registry, which has been approved by the Institutional Review Board (Dartmouth Center for the Protection of Human Subjects).
Study population
Patients were included in the study if they had PCI-stenting An unprotected lesion was defined as one where the patient either had not had prior CABG, had a bypass but no patent grafts to the left coronary system, or the bypass graft was to the right coronary artery only. In this time frame, 221 interventions were done to LMCA lesions, 95 cases were excluded for being protected, and one case was excluded as it was a thrombectomy without any stenting. The final cohort was 125 patients. Only one patient had a prior CABG, which was to the right coronary artery. The decision to perform PCI-stenting versus CABG was dependent upon patient co-morbidities, urgency, adequate surgical targets, patient preference, or physician preference.
In the majority of cases, there were discussions between the cardiologists and cardiothoracic surgeons regarding optimal therapy and surgical candidacy. The use of intravascular ultrasound (IVUS), intra-aortic balloon pump (IABP), and treatment of lesions including bifurcation lesions were left up to the preference of the interventional cardiologists.
Patients were followed for clinical outcomes: new MI, target vessel revascularization (TVR), any revascularization, and death.
Statistical analysis
Means for continuous variables are calculated for different groups (± 1 SD) and compared with Student's t-tests or test 
Results
Study participants
Patient characteristics are presented in Table 1 , and procedural data is presented in Table 2 . Continuous variables are presented with means ± 1 SD. Mean patient follow-up was 1.8 years with longest follow-up of 4.1 years. A prior history of CAD was present in 58% of patients: one patient had a prior CABG and 21.6% of patients had a prior PCI, 50.4% of patients were non-surgical candidates, 3-vessel disease was present in 63.2% of individuals. Cases were either urgent or emergent 87.2% of the time. By using an additive Euroscore value of 6 or more, 74.4% of patients were considered to be at high surgical risk. On average, 2.69 lesions were treated per case with an average of 3.0 stents used. Survival was 89.6% at 30 days, 76.8% at 1 year, and 71.2% at 4 years ( Fig.  1 ) with a cumulative TVR rate of 13.6%.
Bifurcation vs. non-bifurcation lesions
The 51.2% of cases involved bifurcation of the LMCA. Baseline data for bifurcation and non-bifurcation groups are presented in Table 1 . The only significantly different characteristic was EF, with the bifurcation group having a higher mean EF than non-bifurcation group (52.2 vs. 46.1). Patients with lesions treated at the LMCA bifurcation had an increased mortality rate compared to non-bifurcation lesions (37.5% compared to 19.7%). Adjusting for covariates further strengthened the mortality difference between the two groups (Fig. 2) . There was also a nonsignificant trend towards higher in-hospital mortality (12.5% versus 4.9%).
There was no significant difference between cumulative MI or TVR rates. However, there was a non-significant trend of more revascularizations in the bifurcation group (26.6% compared to 16.4%).
Priority designation
With increasing urgency, there was an overall decline in EF (elective 59.4%, urgent 51.6%, emergent 38.0%). Many emergent patients were in shock (62.1%) and not surgical candidates (89.7%). The urgent and emergent groups were more likely to have a positive troponin, acute coronary syndrome, ST-elevation MI and Non-ST-elevation MI, and be in cardiogenic shock. The more emergent procedures had higher risk with higher Parsonnet and Euroscores, and these procedures were more likely to have IABP utilized. Heparin and IIb/IIIa inhibitors were more likely to be utilized in the emergent cases, whereas bivalirudin was more likely to be used in elective cases. With increasing urgency of the procedure, there was an increase in the cumulative mortality (elective 6.3%, urgent 26.3%, emergent 44.8%) (Fig.  3 ). The emergent group had the highest 30-day mortality at 31.0%. Elective and urgent patients had in-hospital mortality comparable to expected mortality when looking at PCI risk models with the elective group at expected and the urgent group mortality 7% better than expected. The emergent group had 40% higher than expected mortality. There was no significant difference between myocardial infarction rates, TVR, or any revascularization between the three priority groups.
Analysis of risk factors for mortality
Cox proportional hazard regression models were utilized to analyze risk factors for mortality. Independent risk factors for mortality were found to be EF ≤ 35% (HR 2.44) and left main bifurcation lesions (HR 2.65) ( Table 4) . Other factors such as IABP use, high Parsonnet score and Euroscore, cardiogenic shock, positive troponin, and emergent priority had significant crude hazard ratios, but these did not result in independently significant ratios in the adjusted hazard ratio model. Of note, stent count, mitral regurgitation ≥ 2+, and acute coronary syndrome were not found to be significant risk factors.
Discussion
The purpose of the present study was to analyze patients who underwent PCI-stenting of the LMCA in a real world application. Our longest patient follow-up was 4 years with a mean follow-up of 1.8 years. Mortality was 10.4% at 30 days, 23.2% at 1 year, and 28.8% at 4 years. Cumulative TVR rate was 13.6%. Our study illustrates the viability of PCI-stenting as a treatment option in patients with LMCA stenosis. Our survival rates are lower than that presented from long-term outcomes from CABG presented in the CASS (Coronary Artery Surgery Study) trial, where they had 10% mortality at 5 years and 26% at 10 years [6] .
Several recent trials have presented outcomes on ULM-CA PCI [24] [25] [26] [27] . A recent meta-analysis of these randomized trials showed no significant difference in MACCE, death, MI when PCI compares with CABG at 1 year [28] . PCI results in higher repeat revascularization rates but lower stroke rates than CABG.
In comparison to these trials, our mortality rate is higher. Our population represents a real-world application of ULM-CA PCI. Our population was at higher risk as evidenced by higher Parsonnet and Euroscores. Patients in our elective priority group had surgical risk score similar to those seen in the SYNTAX trial. This group also had similar cumulative mortality to that seen in SYNTAX at a rate of 6.3%. Our 4 year mortality of 28.8% compares favorably to recent large registry real world data mortality at 30 months of 42.7% [29] .
In our study, bifurcation of the LMCA was found to be an independent predictor of mortality. A recent registry also found an increase in major adverse cardiac events at 2 years with patients with bifurcation lesions [30] . Bifurcation lesions treated with double-stent techniques had worse outcomes at 1 year. Single stent technique was utilized in 33.4% of patients in our study with bifurcation lesions. However, there was no significant difference in outcomes when compared to 2 stent techniques.
EF ≤ 35% was also found to be an independent risk factor for increased mortality. These patient characteristics help further risk stratify patients and may ultimately guide in patient selection for LMCA stenting.
Limitations
This is an observational study. As such, we cannot determine cause-effect relationships and can only suggest associations. Another limitation is our modest sample size which is a direct result of PCI of the LMCA being a relatively rare intervention. This does decrease the power of analyses. Personal operator preference was used with each intervention resulting in variability in the techniques used to treat each lesion, number of stents, stent type, as well as use of IVUS. This makes the comparison of each case difficult and can lead to confounding. The degree and timing of complete revascularization was also not looked at. We also did not look at the types of stents used; while the great majority of stents were DES, some of the interventions utilized bare-metal stents. DES may result in improved outcomes compared to baremetal stents [29, 31] .
Conclusions
PCI of the LMCA remains a viable treatment option for patients in the drug-eluting stent era. It extends options in patients whom are poor candidates for coronary artery bypass grafts. Furthermore, elective LMCA PCI in low-risk CABG patients results in good survival rates. LMCA PCI is associated with a high restenosis rate of 13.6%. EF ≤ 35% and LM bifurcation were independent risk factors for mortality. Further studies regarding appropriate patient selection as well as procedural techniques regarding revascularization should be done to better define which patients may derive the best benefit from ULMCA PCI.
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